Skip to main content
Industry News
Decades of research paved way for COVID-19 vaccines

Scientists at Beth Israel Deaconess Medical Center who had been researching adenovirus vector vaccines for the past two decades quickly shifted their focus to SARS-CoV-2 last year, resulting in a stable, single-dose shot based on adenovirus 26 that is now Johnson & Johnson's COVID-19 vaccine. An HIV vaccine based on the same technology is in Phase 3 testing, and vaccines for Zika and Ebola viruses could follow.

Full Story: